MAZE
Maze Therapeutics Inc.

62
Mkt Cap
$2.02B
Volume
212,857.00
52W High
$43.29
52W Low
$6.71
PE Ratio
-18.67
MAZE Fundamentals
Price
$42.10
Prev Close
$42.08
Open
$41.94
50D MA
$35.43
Beta
1.08
Avg. Volume
427,583.79
EPS (Annual)
$0.0778
P/B
5.33
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital
Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) - Investment analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Maze Therapeutics in a report issued on Thursday...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy
Lifesci Capital upgraded shares of Maze Therapeutics to a "strong-buy" rating in a research note on Thursday...
MarketBeat·8d ago
News Placeholder
Frazier Life Sciences Management L.P. Buys 438,274 Shares of Maze Therapeutics, Inc. $MAZE
Frazier Life Sciences Management L.P. grew its position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) by 10.6% during the 2nd quarter, according to its most recent 13F filing with...
MarketBeat·13d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen
Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·14d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2% - Time to Sell?
Maze Therapeutics (NASDAQ:MAZE) Shares Down 6.2% - What's Next...
MarketBeat·15d ago
News Placeholder
CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE
CW Advisors LLC acquired a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·16d ago
News Placeholder
MAZE Crosses Above Average Analyst Target
In recent trading, shares of Maze Therapeutics Inc (Symbol: MAZE) have crossed above the average analyst 12-month target price of $40.14, changing hands for $41.49/share. When a stock reaches the...
Nasdaq News: Markets·23d ago
News Placeholder
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE
Virtus Investment Advisers LLC bought a new stake in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) in the second quarter, according to its most recent 13F filing with the Securities...
MarketBeat·25d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week High - Time to Buy?
Maze Therapeutics (NASDAQ:MAZE) Reaches New 12-Month High - Here's Why...
MarketBeat·1mo ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4% - Should You Buy?
Maze Therapeutics (NASDAQ:MAZE) Trading Up 8.4% - Should You Buy...
MarketBeat·1mo ago
<
1
2
...
>

Latest MAZE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.